FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2604517038> ?p ?o ?g. }

• W2604517038 endingPage "38060" @default.
• W2604517038 startingPage "38056" @default.
• W2604517038 abstract "// Nicolas Guibert 1,2,4 , Julien Mazieres 1,2,4 , Myriam Delaunay 1,2,4 , Anne Casanova 2,3 , Magali Farella 2,3 , Laura Keller 2,3 , Gilles Favre 2,3,4 and Anne Pradines 2,3 1 Thoracic Oncology Department, Larrey Hospital, University Hospital of Toulouse, Toulouse, France 2 Inserm, Centre de Recherche en Cancérologie de Toulouse, CRCT UMR-1037, Toulouse, France 3 Institut Claudius Regaud, IUCT-Oncopole, Laboratoire de Biologie Médicale Oncologique, Toulouse, France 4 University of Toulouse III (Paul Sabatier), Toulouse, France Correspondence to: Nicolas Guibert, email: // Keywords : immunotherapy, anti-PD-1, non-small-cell lung cancer, KRAS mutation, circulating tumor DNA Received : November 21, 2016 Accepted : March 29, 2017 Published : April 07, 2017 Abstract Objectives: Pseudo-progression is a rare but worrying situation for both clinicians and patients during immunotherapy. Dedicated ir-RECIST criteria have been established to improve this situation. However, this can be sometimes considered inadequate and patients experiencing true progression may then receive inefficient treatments. Additional reliable tools to discriminate pseudo from true progression are thus needed. So far, no biomarker has been identified to distinguish pseudo from true progression. We hypothesize that biomarkers associated with the molecular characteristics of the tumor may be of interest. To avoid a tumor re-biopsy, circulating markers appear to be a less invasive and reproducible procedure. As ctDNA kinetics correlate with the response to treatment in KRAS -mutated adenocarcinoma, we anticipated that this analysis could be of interest. Materials and methods: We monitored the level of KRAS -mutated ctDNA by digital droplet PCR in serial plasma samples from two patients who had experienced pseudo-progression and compared the variations with those from of a patient that had true progression. Results: ctDNA showed rapid and dramatic decreases in pseudo-progressive patients, whereas it was strongly increased in the progressive patient. Conclusions: ddPCR of ctDNA may thus be an additional tool to discriminate pseudo-progression from true progression for tumors that harbor an oncogenic addiction." @default.
• W2604517038 created "2017-04-14" @default.
• W2604517038 creator A5009088330 @default.
• W2604517038 creator A5042784050 @default.
• W2604517038 creator A5055246540 @default.
• W2604517038 creator A5070507586 @default.
• W2604517038 creator A5083251348 @default.
• W2604517038 creator A5083669252 @default.
• W2604517038 creator A5086265255 @default.
• W2604517038 creator A5086678812 @default.
• W2604517038 date "2017-04-07" @default.
• W2604517038 modified "2023-10-01" @default.
• W2604517038 title "Monitoring of <i>KRAS</i>-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma" @default.
• W2604517038 cites W2095382766 @default.
• W2604517038 cites W2100158834 @default.
• W2604517038 cites W2121110176 @default.
• W2604517038 cites W2175763185 @default.
• W2604517038 cites W2328294134 @default.
• W2604517038 cites W2345947373 @default.
• W2604517038 cites W2506635808 @default.
• W2604517038 cites W2560367415 @default.
• W2604517038 cites W2733747219 @default.
• W2604517038 doi "https://doi.org/10.18632/oncotarget.16935" @default.
• W2604517038 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5514971" @default.
• W2604517038 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28445137" @default.
• W2604517038 hasPublicationYear "2017" @default.
• W2604517038 type Work @default.
• W2604517038 sameAs 2604517038 @default.
• W2604517038 citedByCount "70" @default.
• W2604517038 countsByYear W26045170382018 @default.
• W2604517038 countsByYear W26045170382019 @default.
• W2604517038 countsByYear W26045170382020 @default.
• W2604517038 countsByYear W26045170382021 @default.
• W2604517038 countsByYear W26045170382022 @default.
• W2604517038 countsByYear W26045170382023 @default.
• W2604517038 crossrefType "journal-article" @default.
• W2604517038 hasAuthorship W2604517038A5009088330 @default.
• W2604517038 hasAuthorship W2604517038A5042784050 @default.
• W2604517038 hasAuthorship W2604517038A5055246540 @default.
• W2604517038 hasAuthorship W2604517038A5070507586 @default.
• W2604517038 hasAuthorship W2604517038A5083251348 @default.
• W2604517038 hasAuthorship W2604517038A5083669252 @default.
• W2604517038 hasAuthorship W2604517038A5086265255 @default.
• W2604517038 hasAuthorship W2604517038A5086678812 @default.
• W2604517038 hasBestOaLocation W26045170381 @default.
• W2604517038 hasConcept C121608353 @default.
• W2604517038 hasConcept C126322002 @default.
• W2604517038 hasConcept C143998085 @default.
• W2604517038 hasConcept C2776256026 @default.
• W2604517038 hasConcept C2776694085 @default.
• W2604517038 hasConcept C2777701055 @default.
• W2604517038 hasConcept C2778822529 @default.
• W2604517038 hasConcept C2779256057 @default.
• W2604517038 hasConcept C2779529041 @default.
• W2604517038 hasConcept C2779984678 @default.
• W2604517038 hasConcept C2781182431 @default.
• W2604517038 hasConcept C2781187634 @default.
• W2604517038 hasConcept C2781197716 @default.
• W2604517038 hasConcept C502942594 @default.
• W2604517038 hasConcept C526805850 @default.
• W2604517038 hasConcept C55493867 @default.
• W2604517038 hasConcept C71924100 @default.
• W2604517038 hasConcept C86803240 @default.
• W2604517038 hasConceptScore W2604517038C121608353 @default.
• W2604517038 hasConceptScore W2604517038C126322002 @default.
• W2604517038 hasConceptScore W2604517038C143998085 @default.
• W2604517038 hasConceptScore W2604517038C2776256026 @default.
• W2604517038 hasConceptScore W2604517038C2776694085 @default.
• W2604517038 hasConceptScore W2604517038C2777701055 @default.
• W2604517038 hasConceptScore W2604517038C2778822529 @default.
• W2604517038 hasConceptScore W2604517038C2779256057 @default.
• W2604517038 hasConceptScore W2604517038C2779529041 @default.
• W2604517038 hasConceptScore W2604517038C2779984678 @default.
• W2604517038 hasConceptScore W2604517038C2781182431 @default.
• W2604517038 hasConceptScore W2604517038C2781187634 @default.
• W2604517038 hasConceptScore W2604517038C2781197716 @default.
• W2604517038 hasConceptScore W2604517038C502942594 @default.
• W2604517038 hasConceptScore W2604517038C526805850 @default.
• W2604517038 hasConceptScore W2604517038C55493867 @default.
• W2604517038 hasConceptScore W2604517038C71924100 @default.
• W2604517038 hasConceptScore W2604517038C86803240 @default.
• W2604517038 hasIssue "23" @default.
• W2604517038 hasLocation W26045170381 @default.
• W2604517038 hasLocation W26045170382 @default.
• W2604517038 hasLocation W26045170383 @default.
• W2604517038 hasLocation W26045170384 @default.
• W2604517038 hasOpenAccess W2604517038 @default.
• W2604517038 hasPrimaryLocation W26045170381 @default.
• W2604517038 hasRelatedWork W1967429227 @default.
• W2604517038 hasRelatedWork W2035390137 @default.
• W2604517038 hasRelatedWork W2164155795 @default.
• W2604517038 hasRelatedWork W2506635808 @default.
• W2604517038 hasRelatedWork W2604517038 @default.
• W2604517038 hasRelatedWork W3156716706 @default.
• W2604517038 hasRelatedWork W4225989337 @default.
• W2604517038 hasRelatedWork W4306643401 @default.
• W2604517038 hasRelatedWork W4361253018 @default.
• W2604517038 hasRelatedWork W2140890293 @default.

• next